Benitec Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary

• Benitec Biopharma Inc BNTC reported a quarterly adjusted loss of 42 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.32. The mean expectation of eight analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -40 cents to -17 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Benitec Biopharma Inc's reported EPS for the quarter was a loss of 42 cents​.

• The company reported a quarterly loss of $16.15 million.

• Benitec Biopharma Inc shares had risen by 13.0% this quarter and gained 4.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 8.7% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Benitec Biopharma Inc is $28.50, about 53.6% above its last closing price of $13.22

This summary was machine generated from LSEG data September 24 at 12:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)